Car-T

Gilead seals UK deal for Yescarta to treat patients by end of year

10-Oct-2018 By Ben Hargreaves

NHS England has approved CAR-T therapy Yescarta, placing Gilead one-step ahead of Novartis in the race to treat UK adult patients.

Report: Bioprocessing trends 2018-2023

08-Oct-2018 By Flora Southey

Increased cell and gene therapy production and reduced development timelines are listed among bioprocessing trends predicted over the next five years, says consultant.

NORDIC LIFE SCIENCE DAYS

Insight: How Novartis built a ‘money-filled moat’ to market Kymriah

04-Oct-2018 By Flora Southey

Novartis’ experimental marketing strategy, whereby the pharma giant used its scale to insure against failed CAR-T therapies, helped defend Kymriah from competition, says consultant.

Abzena announces licensing agreement for T-cell engineering

24-Sep-2018 By Maggie Lynch

Abzena has signed an antibody humanization agreement with Tmunity Therapeutics a clinical stage T cell therapy company.

Novartis ‘disappointed’ and ‘surprised’ by NICE CAR-T call

21-Sep-2018 By Flora Southey

NICE has deemed Novartis’ CAR T-cell therapy Kymriah too expensive for the UK market.

Novartis further invests in cell and gene therapy manufacture, after Kymriah approval

29-Aug-2018 By Ben Hargreaves

Novartis plans to step up its capabilities of manufacturing cell and gene therapies with a new facility to be built in Stein, Switzerland.

CAR-T comes to Europe: Novartis and Gilead receive EU approvals

28-Aug-2018 By Ben Hargreaves

In a landmark decision, the European Commission has approved both Novartis’ Kymriah and Gilead’s Yescarta for the treatment of patients within the EU.

US FDA approves first non-gene edited allogeneic CAR T-cell candidate for trials

15-Aug-2018 By Flora Southey

Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad.

Regeneron takes $100m stake in bluebird, with ‘long-view’ on drug discovery

07-Aug-2018 By Ben Hargreaves

Regeneron and bluebird bio have announced a partnership to develop six cell therapy drug candidates.

Bluebird’s ‘one-time gene therapy’ receives EMA accelerated assessment

03-Aug-2018 By Ben Hargreaves

Bluebird bio’s LentiGlobin gene therapy has received an accelerated assessment from the EMA for the treatment of transfusion-dependent β-thalassemia.